Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Natural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of... Once completely differentiated, NK cells lack B (CD19-) and T(CD3-) lymphocyte markers and carry their unique CD56+ status instead.
- Mechanism
- Curator reviewed
The predominant targets of NK cells are ‘stressed’ cells with downregulated expression of class I MHC (MHC-I), a common mechanism used by malignant or virus-infected cells to evade recognition by the body’s immune system. In response to encountering these cells, NK cells release two types of proteins, perforins and granzyme B, which attack the target cell’s membrane, damage its organelles, and trigger apoptosis. NK Cell immunotherapy is an emerging anti-cancer strategy, as these cells are able to exert effects without activating the graft-versus-host disease cascade. In addition, their broad mechanism allows for generally safe administration of NK cells that are not immunologically matched to a patient.
- Also known as
- NK Cells
- Code names
- Natural Killer Cells
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with Natural Killer Cell, and which of those have an active Phase 3 trial?